TLR7 and neoplasm: We then performed murine immunization studies using SNAPvaxTM, a peptide-based vaccine that is conjugated to an adjuvant small molecule imidazoquinone-based Toll-like Receptor 7/8 agonist (TLR7/8a) and contains charge-modifying groups to accommodate a wide variety of peptide chemistries; this cancer vaccine platform has yielded robust anti-tumour T cell immunity enabled by enhancements in dendritic cell recruitment and antigen uptake, which in turn reduced tumour growth in multiple models38,39.